The National Comprehensive Cancer Network® (NCCN®) is a leading US authority in clinical practice standards for cancer care. Stockholm3 has been added to the NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer Early Detection, Version 2.2025 [1]. The NCCN guidelines state the probability of high-grade cancer (Grade Group ≥2) may be further defined prior to initial biopsy utilizing tools such as Stockholm3. Stockholm3 is categorized as a 2A-level recommendation indicating uniform consensus among NCCN panel experts that Stockholm3 is an appropriate option based on current evidence. 

“The inclusion of Stockholm3 in the NCCN guidelines confirms its clinical relevance and further establishes our test as a powerful tool in the early detection of high-grade prostate cancer,” said Martin Steinberg, Executive Chairman of A3P Biomedical. 

“This is an important milestone in our mission to advance precision diagnostics in prostate cancer,” Martin Steinberg concluded. 

The NCCN’s recognition adds to the growing international momentum of Stockholm3 and strengthens its positioning for broader adoption across clinical settings. With the burden of prostate cancer continuing to rise globally, there is increasing demand for screening tools that enable more accurate, earlier, and less invasive diagnosis. 

[1] Moses, KA, Sprenkle PC, Bahler C, Box G, Carlsson SV, Catalona WJ, Dahl DM, Dall’Era M, Davis JW, Drake BF, Eggener S, Etzioni RB, Farrington TA, Garraway IP, Jarrard D, Kauffman E, Kaye D, Kibel AS, LaGrange CA, Lotan T, Maroni P, Reys B, Salami SS, Sanchez A, Seibert TM, Shaneyfelt TM, Shoag J, Smaldone MC, Sonn G, Tyson II MD, Vapiwala N, Wake R, Washington III S, Yu A, Yuh B, Freedman-Cass D, Howley R, Kovach E. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer Early Detection v2.2025. Accessed 06/24/25. To view the most recent and complete version of the guideline, go online to NCCN.org